Advertisement
BRKR vs MEDP
Which Stock Would AI Choose? Bruker Corporation (BRKR) vs. Medpace Holdings (MEDP) Stock Comparison
Key Takeaways
- BRKR operates in scientific instruments and analytical solutions for life sciences and materials research, while MEDP provides clinical research services as a contract research organization (CRO).
- Both companies serve the healthcare and life sciences sectors but differ in exposure: BRKR focuses on hardware and technology platforms, MEDP on outsourced clinical trial management.
- Recent market activity has shown varying momentum between the two, influenced by broader sector trends in biotech funding and research spending.
- BRKR exhibits sensitivity to capital expenditure cycles in research institutions, whereas MEDP benefits from sustained demand for clinical development outsourcing.
- Risk profiles differ, with BRKR facing supply chain and technology adoption variables, and MEDP navigating regulatory and trial execution factors.
- Market sentiment reflects ongoing evaluation of relative growth stability amid evolving life sciences investment patterns.
Introduction
BRKR and MEDP represent distinct segments within the life sciences ecosystem, making them relevant for investors and traders seeking exposure to healthcare innovation and research infrastructure. This comparison examines their business models, recent performance dynamics, and market positioning to assist those evaluating sector-specific opportunities. Portfolio managers, growth-oriented investors, and traders monitoring relative strength in healthcare services versus instrumentation may find the analysis useful for understanding trade-offs in volatility, growth drivers, and sector cyclicality.
BRKR Overview and Recent Performance
Bruker Corporation (BRKR) develops and manufactures scientific instruments, including mass spectrometers, nuclear magnetic resonance systems, and surface plasmon resonance tools used in life sciences, materials research, and industrial applications. In recent weeks, the stock has reflected broader market responses to research funding trends and capital spending by academic and pharmaceutical institutions. Performance has been shaped by investor focus on technology upgrades and demand for advanced analytical capabilities amid ongoing innovation in drug discovery and materials science. Sentiment has incorporated assessments of order backlogs and international exposure, contributing to measured price movements aligned with sector rotation patterns.
MEDP Overview and Recent Performance
Medpace Holdings (MEDP) operates as a full-service contract research organization (CRO) that manages clinical trials for pharmaceutical, biotechnology, and medical device companies. Recent market activity has highlighted the company's positioning within the expanding clinical development outsourcing market. Stock behavior in recent weeks has responded to indicators of trial pipeline strength and client retention rates, influenced by sustained biopharma research and development activity. Performance has incorporated evaluations of operational efficiency and regulatory navigation, resulting in price action that tracks demand for outsourced services in a competitive CRO landscape.
Trending AI Robots
Tickeron’s Trending AI Robots page curates a selection of high-performing AI trading bots from hundreds available across its platform. These bots trade thousands of different tickers using varied strategies, timeframes, and risk parameters. Only those demonstrating the strongest alignment with prevailing market conditions earn placement in the trending section, where users can review performance statistics, win rates, and drawdown metrics that often range from conservative to aggressive profiles. The bots encompass diverse styles including trend-following, mean-reversion, and momentum approaches tailored to individual equities or broader baskets. This resource allows traders to explore data-driven options suited to current volatility and sector dynamics. Explore the full selection on the Trending AI Robots page for additional insights.
Head-to-Head Comparison
BRKR and MEDP differ fundamentally in business models: Bruker Corporation (BRKR) centers on capital equipment and instrumentation sales with recurring service revenue, while Medpace Holdings (MEDP) generates fees through long-term clinical trial management contracts. Growth drivers contrast sharply, with BRKR tied to instrumentation adoption cycles and research budgets, and MEDP linked to biopharma outsourcing volumes and trial complexity. Recent momentum has varied based on respective exposures to capital expenditure sensitivity versus service demand stability. Risk factors include BRKR’s vulnerability to technology shifts and supply constraints versus MEDP’s dependence on client pipelines and regulatory timelines. Sector exposure overlaps in life sciences yet diverges in hardware versus services orientation, leading to differentiated market sentiment influenced by macroeconomic factors affecting research spending and drug development activity.
Tickeron AI Verdict
Based on observable factors such as trend consistency in service-oriented demand and relative positioning within clinical outsourcing growth, Tickeron’s AI models currently assign a higher probabilistic preference to MEDP over BRKR in the near term. This assessment draws from patterns in stability of contract-based revenue streams and sector tailwinds, though outcomes remain subject to broader market variables and execution risks.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BRKR is a StrongBuy and MEDP is a StrongBuy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
BRKR’s FA Score shows that 1 FA rating(s) are green whileMEDP’s FA Score has 2 green FA rating(s).
- BRKR’s FA Score: 1 green, 4 red.
- MEDP’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
BRKR’s TA Score shows that 3 TA indicator(s) are bullish while MEDP’s TA Score has 5 bullish TA indicator(s).
- BRKR’s TA Score: 3 bullish, 2 bearish.
- MEDP’s TA Score: 5 bullish, 3 bearish.
Price Growth
BRKR (@Medical/Nursing Services) experienced а +3.81% price change this week, while MEDP (@Medical Specialties) price change was +11.84% for the same time period.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was -5.78%. For the same industry, the average monthly price growth was -7.49%, and the average quarterly price growth was -21.89%.
The average weekly price growth across all stocks in the @Medical Specialties industry was -1.55%. For the same industry, the average monthly price growth was +2.80%, and the average quarterly price growth was +1.12%.
Reported Earning Dates
BRKR is expected to report earnings on Aug 05, 2026.
MEDP is expected to report earnings on Oct 26, 2026.
Industries' Descriptions
@Medical/Nursing Services (-5.78% weekly)The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
@Medical Specialties (-1.55% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
| BRKR | MEDP | BRKR / MEDP | |
| Capitalization | 9.2B | 16.8B | 55% |
| EBITDA | 306M | 591M | 52% |
| Gain YTD | 28.622 | 7.074 | 405% |
| P/E Ratio | 74.88 | 35.33 | 212% |
| Revenue | 3.46B | 2.68B | 129% |
| Total Cash | N/A | 653M | - |
| Total Debt | 1.67B | 122M | 1,370% |
BRKR | MEDP | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 77 | 86 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 50 Fair valued | 80 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 26 | |
SMR RATING 1..100 | 92 | 15 | |
PRICE GROWTH RATING 1..100 | 36 | 37 | |
P/E GROWTH RATING 1..100 | 7 | 41 | |
SEASONALITY SCORE 1..100 | 85 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
BRKR's Valuation (50) in the Medical Specialties industry is in the same range as MEDP (80) in the Miscellaneous Commercial Services industry. This means that BRKR’s stock grew similarly to MEDP’s over the last 12 months.
MEDP's Profit vs Risk Rating (26) in the Miscellaneous Commercial Services industry is significantly better than the same rating for BRKR (100) in the Medical Specialties industry. This means that MEDP’s stock grew significantly faster than BRKR’s over the last 12 months.
MEDP's SMR Rating (15) in the Miscellaneous Commercial Services industry is significantly better than the same rating for BRKR (92) in the Medical Specialties industry. This means that MEDP’s stock grew significantly faster than BRKR’s over the last 12 months.
BRKR's Price Growth Rating (36) in the Medical Specialties industry is in the same range as MEDP (37) in the Miscellaneous Commercial Services industry. This means that BRKR’s stock grew similarly to MEDP’s over the last 12 months.
BRKR's P/E Growth Rating (7) in the Medical Specialties industry is somewhat better than the same rating for MEDP (41) in the Miscellaneous Commercial Services industry. This means that BRKR’s stock grew somewhat faster than MEDP’s over the last 12 months.
| BRKR | MEDP | |
|---|---|---|
| RSI ODDS (%) | N/A | 2 days ago 86% |
| Stochastic ODDS (%) | 2 days ago 74% | 2 days ago 80% |
| Momentum ODDS (%) | 2 days ago 72% | 2 days ago 75% |
| MACD ODDS (%) | N/A | 2 days ago 83% |
| TrendWeek ODDS (%) | 2 days ago 70% | 2 days ago 76% |
| TrendMonth ODDS (%) | 2 days ago 73% | 2 days ago 76% |
| Advances ODDS (%) | 24 days ago 69% | 16 days ago 76% |
| Declines ODDS (%) | 6 days ago 73% | 6 days ago 63% |
| BollingerBands ODDS (%) | 2 days ago 90% | 2 days ago 76% |
| Aroon ODDS (%) | N/A | 2 days ago 76% |
Advertisement
MEDP and
Correlation & Price change
A.I.dvisor indicates that over the last year, MEDP has been loosely correlated with CRL. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if MEDP jumps, then CRL could also see price increases.
| Ticker / NAME | Correlation To MEDP | 1D Price Change % | ||
|---|---|---|---|---|
| MEDP | 100% | -0.73% | ||
| CRL - MEDP | 53% Loosely correlated | -1.18% | ||
| TMO - MEDP | 47% Loosely correlated | -0.71% | ||
| BRKR - MEDP | 43% Loosely correlated | -2.74% | ||
| RVTY - MEDP | 39% Loosely correlated | -2.39% | ||
| ICLR - MEDP | 39% Loosely correlated | -2.68% | ||
More | ||||